| 2.345 -0.005 (-0.21%) | 10-01 15:57 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.74 | 1-year : | 3.2 |
| Resists | First : | 2.34 | Second : | 2.74 |
| Pivot price | 2.33  |
|||
| Supports | First : | 2.31 |
Second : | 2.28 |
| MAs | MA(5) : | 2.34 |
MA(20) : | 2.33 |
| MA(100) : | 1.68  |
MA(250) : | 3.41 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 100 | D(3) : | 96.2 |
| RSI | RSI(14): 74 | |||
| 52-week | High : | 6.25 | Low : | 0.73 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AUGX ] has closed below upper band by 10.2%. Bollinger Bands are 95.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 38 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.35 - 2.36 | 2.36 - 2.37 |
| Low: | 2.32 - 2.33 | 2.33 - 2.35 |
| Close: | 2.33 - 2.35 | 2.35 - 2.37 |
Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live and Augmedix Notes solutions that provide pre-visit documentation, such as pre-charting and digitization of previous records/patient history; during-visit documentation, including medical notes, care gap reminders, HCC reminders, and after-visit summaries; and post-visit documentation consisting of coding, orders, and referrals. The company enables clinicians to access its applications through mobile devices, such as smartphones or Google Glass. It serves health systems and specialty groups. The company was founded in 2013 and is headquartered in San Francisco, California.
Wed, 02 Oct 2024
Commure Completes Merger with Augmedix - Stock Titan
Thu, 11 Apr 2024
Insider Sell: Augmedix Inc's (AUGX) Chief Strategy Officer Ian Shakil Sells 92,787 Shares - Yahoo Finance
Tue, 28 Nov 2023
Augmedix Faces 'Epic' Challenges In The AI Healthcare Innovation Sector (NASDAQ:AUGX) - Seeking Alpha
Tue, 07 Nov 2023
Augmedix, Inc. (NASDAQ:AUGX) Q3 2023 Earnings Call Transcript - Insider Monkey
Tue, 12 Sep 2023
Are Medical Stocks Lagging Augmedix (AUGX) This Year? - Yahoo News Singapore
Fri, 16 Jun 2023
Is Augmedix (AUGX) Stock Outpacing Its Medical Peers This Year? - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 49 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 1.5 (%) |
| Held by Institutions | 84.7 (%) |
| Shares Short | 1,070 (K) |
| Shares Short P.Month | 1,570 (K) |
| EPS | -0.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.2 |
| Profit Margin | -46.3 % |
| Operating Margin | -63.9 % |
| Return on Assets (ttm) | -30.7 % |
| Return on Equity (ttm) | -329.8 % |
| Qtrly Rev. Growth | 26.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.04 |
| EBITDA (p.s.) | -0.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -5 |
| PEG Ratio | 0 |
| Price to Book value | 11.19 |
| Price to Sales | 2.25 |
| Price to Cash Flow | -7.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|